Previous 10 | Next 10 |
home / stock / bctxf / bctxf news
BriaCell Therapeutics ( OTCQB:BCTXF -19.9% ) announce a non-brokered private placement of up to ~8.57M common shares for gross proceeds of up to ~ C$0.6M at a price of C$0.07/share. More news on: BriaCell Therapeutics Corp., Read more ...
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 20, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for adva...
Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress. Publicly-traded securities of BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) will remain halted for the duration of CEO Dr. Williams ...
BERKELEY, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces that the Company will be pres...
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces tha...
BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announce...
BERKELEY, Calif. and VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to ...
BERKELEY, Calif. and VANCOUVER, British Columbia, May 28, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced...
BERKELEY, Calif., and VANCOUVER, British Columbia, May 13, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announce...
BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announc...
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Company Name:
BCTXF Stock Symbol:
OTCMKTS Market:
BriaCell Therapeutics Website:
Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, April 10-15 and May...
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies f...
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies f...